Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: January 16, 2025
Principal Executive Office: Marseille, France
Context: This filing incorporates by reference a press release dated January 16, 2025 (Exhibit 99.1). The document serves to update investors and incorporates the referenced material into the company's registration statements on Form F-3 and Form S-8.
Key Financial Metrics
The provided filing text is a cover sheet and incorporation by reference document. It does not contain specific financial data. Consequently, the following metrics are not available in this text:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not disclose specific material changes in financial performance or operations compared to prior periods. The content is limited to the administrative incorporation of a press release.
Guidance, Outlook, and Management Commentary
Management Commentary: The filing explicitly excludes a quotation from Jonathan Dickinson, Chief Executive Officer and Chairman of the Executive Board, as well as references to the 43rd Annual J.P. Morgan Healthcare Conference and related internet links from the incorporation by reference.
Guidance and Risks: No specific guidance, outlook, risks, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Review the full text of the Press Release dated January 16, 2025 (Exhibit 99.1), as the financial and operational details are contained therein rather than in this cover document.
- Verify the specific content of the excluded CEO quotation and J.P. Morgan Healthcare Conference references, as these were omitted from the incorporation by reference.
- Confirm the status of the registration statements on Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031) to understand how this press release impacts future capital raising activities.